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Discovery of Plant Extracts That Delay Yeast Chronological Aging through Different 
Signaling Pathways  
 
Vicky Lutchman, M.Sc. 
 
The yeast Saccharomyces cerevisiae is a beneficial organism for the discovery of genes, 
signaling pathways and chemical compounds that slow cellular and organismal aging in 
eukaryotes across phyla. As a first step towards uncovering novel aging-delaying chemical 
compounds, I conducted a screen of a library of plant extracts for those that can extend yeast 
chronological lifespan. My screen revealed six plant extracts that increase yeast chronological 
lifespan considerably more efficiently than any of the longevity-extending chemical compounds 
yet described. I show that each of the six plant extracts is a geroprotector which delays the onset 
and decreases the rate of yeast chronological aging by eliciting a hormetic stress response. 
Because the rate of aging in yeast is controlled by a network of integrated signaling pathways 
and protein kinases, I assessed how single-gene-deletion mutations eliminating each of these 
pathways and kinases affect the aging-delaying efficiencies of the six plant extracts. My findings 
imply that these extracts slow aging in the following ways: 1) plant extract 4 decreases the 
efficiency with which the pro-aging TORC1 pathway inhibits the anti-aging SNF1 pathway; 2) 
plant extract 5 mitigates two different branches of the pro-aging PKA pathway; 3) plant extract 6 
coordinates processes that are not assimilated into the network of presently known signaling 
pathways/protein kinases; 4) plant extract 8 diminishes the inhibitory action of PKA on SNF1; 5) 
plant extract 12 intensifies the anti-aging protein kinase Rim15; and 6) plant extract 21 inhibits a 
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1.1 The budding yeast Saccharomyces cerevisiae as an advantageous model 
organism for unveiling mechanisms of cellular aging in multicellular eukaryotes  
The single-celled budding yeast, Saccharomyces cerevisiae is one of the most 
commonly utilized organisms in aging research. [1, 2] This is due to many factors, but 
one of the most underlying reasons is because the longevity-defining genes and signaling 
pathways discovered in yeast have been shown to define organismal longevity in 
eukaryotes across phyla. [3, 4] Other factors include the amenability of yeast to genetic, 
cell biological, comprehensive biochemical, system biological and many other forms of 
analyses. [1-6]. These factors pave way for using yeast for gaining fundamental 
mechanistic insights into longevity processes and their regulation not only in yeast, but 
also in eukaryotic organisms that are more evolutionarily distant. [5, 6]   
S. cerevisiae also provides ease in experimentation due to the fact that its short 
lifespan can easily be quantified allowing rapid progress in comparison with other, more 
complex organisms. [5] This rapidity gives way for accelerated progress in defining 
molecular mechanisms defining longevity within the organism as well as identifies 
numerous factors underlying its longevity. [5] The preferable source of carbon and/or 
energy for this unicellular organism is glucose [14], permitting easy and efficient 
scientific adjustment for caloric restriction (CR) experimentation and also providing high 
cost efficiency.  
S. cerevisiae is an advantageous unicellular model organism in that it unveils 




of more complex cellular aging in multicellular eukaryotes, due to the evolutionary 
conserved effects on lifespan in multicellular organisms, depicted in Figure 1.1. [2, 6] 
Despite the fact that there are many differences as well as complexities concerning 
humans in relation to yeast, the study of aging in yeast provides many key insights 
amongst the aging pathways which is also illustrated in Figure 1.1 [5, 6] Provided that 
the entire yeast genome has been well-characterized, it can be shown that a substantial 
portion of gene sequences have homologs compared to that of the mammalian sequences. 
[13,15] With this in mind, the topic of longevity pathways which concern human aging 
and disease, S. cerevisiae will continue to serve as an attractive model organism of study. 
[4] 
 
Figure 1.1. Aging pathways are evolutionarily conserved throughout phyla. Aging 
pathways exhibit many similar features in the unicellular organism, S. cerevisiae, and in 





1.2 Replicative and chronological models of yeast aging  
One of the main aspects in research pertaining to longevity is to establish the 
fundamental concepts which contribute to the nature of aging as well as its associated 
diseases. [5] This is where the different specificity concerning the lifespan of S. 
cerevisiae and how it is differentiated come to hand. In budding yeast, there are two main 
approaches in which yeast can be studied in accordance to its lifespan; the replicative 
lifespan approach and the chronological lifespan approach.  
The replicative lifespan (RLS) is defined as the study of the number of 
asymmetric mitotic divisions a mother cell can undergo preceding cell cycle arrest, as 
illustrated in Figure 1.2. [1] The chronological lifespan is defined as the study of the 
viability of a cell over time after cell cycle arrest. The viability of a cell is categorized as 
the ability of re-entry into the cell-cycle in response to the addition of new essential 
nutrients, which is also illustrated in Figure 1.2. [1] Studies of yeast longevity through 
replicative and chronological lifespan assays under controllable laboratory settings have 
advanced our understanding of longevity regulation; these studies have also revealed 
longevity-defining cellular processes and mechanisms within a single cell in eukaryotic 
organisms across phyla. [2] 
The replicative lifespan (RLS): 
S. cerevisiae reproduces through the means of asymmetric cell division. The 
concept of RLS in S. cerevisiae is thought to emulate the longevity of dividing, 
mitotically active cells in multicellular eukaryotic organisms, which highlights the 





Figure 1.2. Replicative vs. chronological assays most commonly used in experiments 
with yeast. Replicative aging in yeast is measured over generations as the number of 
daughter cells produced by a mother cell. Chronological aging in yeast is assessed as 
viability of the cells over time after cell cycle arrest; cell viability in this assay is defined 
as the ability of the cell to proliferate if transferred to a nutrient-rich medium. [9] 
 
RLS research focuses on this asymmetric cell division through the use of a standard 
tetrad microscope equipped with a micromanipulator. [2, 4] Within laboratory condition, 
budding progeny of the mother cell is removed with using this micromanipulator and the 
cumulative number of asymmetric mitotic divisions is counted in order to assess how 
many of these divisions a single mother cell can undergo. [2] Recent studies stray from 
this micromanipulator method, and rather involve selectively eradicating daughter cells 
or microfluidic flow chambers. Although these newly introduced high-throughput 
methods are still being perfected, the micromanipulator method still remains the standard 
method for RLS assays. [4] 
The illustration depicted in Figure 1.3 simplifies the differences between the 




chronological lifespan, as well as the damage accumulated over time within each assay. 
The mother cell within the RLS assay undergoes longevity-defined cellular processes. 
Figure 1.3 portrays the processes of aging for RLS which take place in three defined and 
consecutive stages; the early, intermediate and late age stages, respectively. These 
cellular processes are also confounded to various cellular compartments, where longevity 
is coordinated and co-regulated. Over time, the mother cell progressively accumulates 











Figure 1.3. Damage accumulation in aging yeast for chronological vs. replicative 
lifespan assays. For CLS, age-related damage accumulates in non-dividing cells, 
whereas for RLs, the damage is inherited by the asymmetric mitotically dividing daughter 
cells. In chronologically aging yeast, ethanol accumulates within the medium, which later 
converts to acetic acid and stimulates senescence. Within the chronologically aging cell, 
on the other hand, damage accumulation is built up from oxidized proteins as well as 
impaired mitochondria, which also contributes to cellular senescence. In replicatively 
aging yeast, cellular senescence is obtained through oxidized proteins and impaired 
mitochondria (alike CLS), along with nuclear extrachromosomal rDNA circles. Over 
time, the daughter cells can inherit an ample amount of accumulated damage which can 
cause premature aging due to the very aged mother cells. [5]          
 
One of the distinct forms of molecular damage within RLS, which is specific to the 
mother cell, is the accumulation of extrachromosomal ribosomal DNA (rDNA) circles, 
known as ERCs (Figure 1.3). These ERCs result from the homologous recombination 
within the rDNA consequentially forming a self-replicating circular DNA molecule 
which is kept in the nucleus of the mother cell. This ERC is therefore passed on to the 




specifically histone deacetylase Sir2, influence the formation of ERCs and are therefore a 
very important factor when observing RSL of yeast. Sirtuins are a group of NAD+-
dependent protein deacetylases found to be of major importance in ample studies. [5, 16] 
Much remains unclear and is yet to be discovered concerning Sir2 in its role of 
replicative senescence, but some studies revealed that its overexpression increases RLS 
whereas its deletion decrease the RLS. [5]  
 
The chronological lifespan (CLS):  
In contrast to yeast RLS, in chronological lifespan (CLS) of yeast, the age-related 
damage accumulated over time is observed within non-dividing cells, where a threshold 
is met and the cells can no longer re-enter the cell cycle (Figure 1.3). The CLS paradigm 
is studied due to the fact that it serves as straightforward model for cellular longevity as 
well as mimics the aging of post-mitotic, non-dividing cells in that of a more complex 
eukaryotic organism. [2] The CLS is assessed within the controlled environment of the 
laboratory within a liquid media where its distinct cellular processes are evaluated before 
cellular cessation. These distinct cellular processes comprise of: cellular growth and 
division, cellular stress response and death, organelle biogenesis, interorganellar 
communication, cellular metabolism, and macromolecular homeostasis. [1] 
Within laboratory conditions, the CLS assay is achieved through the use of 
clonogenic assay. This clonogenic assay quantifies the percentage of yeast cell viability 
at different time points during growth in a liquid medium of 2% glucose, followed by 
assessing its ability to form colonies on fresh solid nutrient-rich media. [2, 5] In general, 




source. As the yeast cells consume the glucose through fermentation, ethanol is the main 
product of such fermentation and it accumulates in the extracellular environment. Once 
the glucose reserve is completely depleted, the cells begin metabolize the ethanol within 
the extracellular environment through mitochondrial respiration, as depicted in Figure 
1.4.  
Studies suggest that through the process of chronological aging, the mitochondrial 
production of reactive oxygen species (ROS) causes oxidative damage to proteins, lipids 
and DNA within the mitochondria. Concomitantly with the age-related ROS 
accumulation in chronologically aging yeast, cell resistance to oxidative stress has been 
shown to decrease. [5] One of the key factors pertaining to this oxidative stress is the 
accumulation of acetic acid. As the chronologically aging yeast persists to use ethanol as 
its secondary carbon source for mitochondrial respiration, acetic acid (as well as some 
other organic acids) are leeched out into the extracellular environment. Studies have 
shown that the presence of acetic acid limits the lifespan in chronologically aging yeast 
due to the fact that acetic acid (along with other acidic organic by-products) acidifies the 





Figure 1.4. The metabolism of carbon sources in the chronologically aging S. 
cerevisiae. Under non-caloric restriction conditions on 2% glucose, the yeast cells 
metabolize this carbon source into ethanol. As glucose is depleted over time, ethanol is 
then metabolized through mitochondrial respiration, with acetic acid as the final product 
secreted into the extracellular environment. Under caloric restriction conditions on 0.5% 
glucose, glucose is metabolized not through fermentation but through mitochondrial 
respiration, thus extending chronological lifespan and increasing resistance to oxidative 
stress. [5]. 
 
 Other factors that define the longevity of chronologically aging yeast are so-called 
“biomolecular networks”. [1] These biomolecular networks operate at several distinct 
checkpoints during the CLS of S. cerevisiae; the entry into and progression through each 
of these checkpoints is regulated by a limited number of protein regulators. The protein 
regulators act synergistically to coordinate the pace of the aging processes, thus defining 
yeast CLS. [1] 
The CLS checkpoints occur in several consecutive growth phases, which are 




(so-called early-life checkpoints), diauxic, post-diauxic and stationary (so-called late-life 
checkpoints) growth phases. [1] As previously mentioned, cells that are inoculated into a 
glucose-rich medium with 2% glucose, progress quickly through the 
exponential/logarithmic phase. When 50% of glucose supplies are consumed, glycogen 
synthesis begins. The diauxic shift phase is defined as a phase in which glucose has been 
fully depleted, cells reduce their growth rate and then enter the post-diauxic phase; during 
this post-diauxic phase, yeast cells undergo slow respiratory growth using the glucose 
fermentation products ethanol and acetate as carbon sources (Figure 1.4). [12]     
 
 
Figure 1.5. Growth curve for yeast cultured in glucose-rich medium initially 
containing 2% glucose. This curve illustrates the different phases through which 
chronologically aging yeast progress. A limited number of proteins and cellular processes 
orchestrates the progression of chronologically aging yeast through each of these phases.  
[11] 
 
Each checkpoint the yeast cell undergoes within its lifespan is monitored by 
several “master regulator proteins” which regulate the intercellular concentrations of 
various metabolic pathways as well as the rates in which they proceed, therefore 




modulate the concentrations of some key metabolites and the rates of their interorganellar 
flow. Because of this, these master regulator proteins define the efficiency of such 
longevity-defining cellular processes as cellular metabolism, cellular division, organelle 
biogenesis, interorganellar communication, stress response, macromolecular homeostasis 
and cellular senescence. [1] Although each of these processes is a program for 
maintaining the overall survival of yeast, none of them is a program for defining aging. 
Rather, a dynamic equilibrium between these various processes is a key factor which 
defines longevity of chronologically aging yeast. [1] 
 Another main feature to the study of chronologically aging yeast is its ability to 
enter into a characteristic state of cell cycle arrest known as quiescence. Such entry into a 
state of quiescence has been shown to delay yeast aging because it allows yeast to adapt 
to different nutrient stresses and, thus, to delay aging inflicted by environmental stresses. 
The aging of yeast that enter the quiescent state is a valuable model for understanding 
aging of post-mitotic mammalian cells; this is because this state of quiescence is a state in 
which cells undergo complex changes in their metabolism and physiology.  
 As discussed previously, yeast CLS is mainly monitored using cells grown in a 
glucose-rich liquid medium, progressing through the stationary phase of starvation and 
ultimately dying because of the excessive endogenous stress. Because yeast cells 
progressing through the stationary phase undergo starvation, these cells exit cell cycle in 
the G1 phase and enter a non-dividing phase in which cells undergo characteristic 
morphological, biochemical and physiological changes to adapt to the environmental 
stress (Figure 1.6). [12] This non-dividing phase of the cell cycle is known as the G0 




quiescent cells may re-enter the cell cycle to proliferate once again. Under starvation 
conditions, not all cells exit the cell cycle and enter the quiescent state; some cells enter a 
different state to become nonquiescent cells. Due to the starvation conditions, most cells 
eventually die and are therefore broken down; this releases some nutrient components 
that can then be reused by cells that are still alive to maintain their survival.      
 
 
Figure 1.6. Model of quiescent and non-quiescent states in yeast. After glucose 
depletion, during the diauxic shift, cells can enter the G0 quiescent state. Cells in this 
quiescent state can re-enter the cell cycle if and when nutrients are replenished. In the 
quiescent state, cells undergo different programs of adaptation in order to survive under 
starvation conditions. Cells which do not enter the quiescent modification state 
(nonquiescent) continue within the mitotic cell cycle, where most of which become 
senescent, apoptotic or necrotic. These cells are eventually released as nutrients and 
replenish those cells that have entered the G0 quiescent state. The few nonquiescent cells 
may retain the ability to reproduce when nutrients become available once again. [8] 
  
 Quiescent cells where once thought to be a dormant state for the cells, but have 
recently been found to progress through a distinctive adaptive phases of cellular 
programming; such programming enables cells to live longer and to withstand 
environmental stresses. [12] These quiescent programs overcome environmental 
challenges through the configuration of various signaling pathways as well as regulating 




role of signaling pathways and yeast longevity is of much importance due to their 
individual anti- or pro-aging characteristics.  
 
1.3 The rate of chronological aging in yeast is controlled by a network of 
integrated signalling pathways and protein kinases  
Certain signaling pathways and protein kinases converge into a network that 
controls the rate of chronological aging in yeast, as shown in Figure 1.7. In 
chronologically aging yeast, this network integrates the following: 1) the pro-aging 
TORC1 (target of rapamycin complex 1) pathway; 2) the pro-aging PKA (protein kinase 
A) pathway; 3) the pro-aging PKH1/2 (Pkb-activating kinase homolog) pathway; 4) the 
anti-aging SNF1 (sucrose non-fermenting) pathway; 5) the anti-aging ATG (autophagy) 
pathway; 6) the pro-aging protein kinase Sch9, which is stimulated by the TORC1 and 
PKH1/2 pathways; and 7) the anti-aging protein kinase Rim15, which is inhibited by the 
TORC1, PKA and PKH1/2 pathways. This network of signaling pathways and protein 
kinases coordinates certain longevity-defining cellular processes, including stress 
responses, protein synthesis in the cytosol and mitochondria, maintenance of nuclear and 
mitochondrial genomes, autophagy, mitochondrial respiration, peroxisome biogenesis, 
gluconeogenesis, lipid metabolism, glyoxylate cycle, glycogen synthesis and degradation, 





Figure 1.7. A network of pro-aging and anti-aging pathways operating in 
chronologically aging yeast. This signaling network controls the relative rates of a 
distinct set of cellular processes. 
 
The pro-aging TORC1 (target of rapamycin complex 1) pathway: 
The TOR gene encodes an evolutionarily conserved master regulator of longevity in 
all eukaryotic organisms. This master regulator protein is called TOR (target of 
rapamycin). While higher eukaryotes possess only one TOR protein assembled with 
certain interacting proteins into the TORC1 complex, the yeast S. cerevisiae has two 
TOR proteins (which known as Tor1p and Tor2p) interacting with a partially overlapping 
set of proteins. [14] In S. cerevisiae, an interaction of Tor1p and Tor2p with three other 
proteins results in the assembly of the TORC1 complex. [14] An association between 
Tor2p and five other proteins forms the TORC2 complex. [14] The TORC2 complex 
regulates cell polarity and the actin cytoskeleton. [14] The TORC1 regulates cell growth, 
the transition from the logarithmic growth to the diauxic and the stationary growth 




in cell progression through different growth phases, TORC1 is a main focus of many 
studies pertaining to aging. [14] The TORC1 responds to nutrient availability, being 
especially sensitive to the availability of nitrogen sources.  [14] The TORC1 pathway has 
been found to be inhibited by rapamycin (unlike the TORC2 pathway) and by nitrogen 
starvation. [12, 14] The inhibition of TORC1 decreases protein synthesis, delays the 
onset of autophagy and prevents the entry into the G0 (quiescent) state of the cell cycle. 
[12, 14] The inhibition of the TORC1 pathway by rapamycin or nitrogen starvation 
activates several stress-responsive transcriptional factors, thereby causing the 
reprogramming of gene expression and extending longevity in yeast. [14] There are two 
main protein targets of TORC1, namely Tap42p (regulator of protein phosphatase 2A) 
and Sch9p. These two proteins regulate most of the cellular processes known to be under 
control of the TORC1 signaling pathway. [14] 
 
The pro-aging protein kinase Sch9, which is stimulated by the TORC1 and PKH1/2 
pathways: 
Sch9 is one of the key regulators of cell cycle initiation, thus contributing to cell size 
control. [14] Sch9 also regulates ribosome assembly. [14] Therefore, a deletion of the 
SCH9 gene makes yeast cells very small. Sch9 is dually regulated by the TORC1 and the 
PKH1/2 signaling pathways. Such dual regulation of Sch9 enables the efficient control of 
yeast growth and survival in response to intracellular and external cues. [18] The 
inhibition of TORC1 by way rapamycin dephosphorylates and inactivates Sch9. [14] This 
inactivation of Sch9 activates the nuclear translocation of the protein kinase Rim15p, one 




state of cellular quiescence results in the reprogramming of gene expression in yeast; 
such reprogramming increases stress resistance and extends longevity. It has also been 
shown that lack of Sch9 or TORC1 decreases the concentrations of ethanol and acetic 
acid in growth medium as well as increases the efflux of glycerol from the yeast cell. [6] 
These changes in the concentrations of ethanol, acetic acid and glycerol extend yeast 
chronological lifespan via mechanisms similar to those responsible for lifespan extension 
by caloric restriction. [6] 
 
The pro-aging PKH1/2 (Pkb-activating kinase homolog) pathway: 
In addition to being regulated by TORC1, Sch9 is under control of the PKH1/2 
signaling pathway. While TORC1 phosphorylates the serine and threonine residues at the 
C-terminus of Sch9, the nutrient-sensing protein kinases Pkh1 and Pkh2 phosphorylate 
the threonine 570 (T570) residue at the activation loop of the kinase domain of Sch9. [18] 
Sch9 is fully active only if phosphorylated in these various positions by TORC1 and 
PKH1/2. [18] Both, Pkh1 and Pkh2, are known to be activated by sphingolipids. [18, 19] 
Sphingolipids are signaling molecules implicated in the regulation of cellular growth and 
migration, senescence, inflammation, differentiation, and apoptotic cell death. [18] 
Sphingolipid synthesis is known to be initiated by an enzyme inhibited by myriocin. [20] 
The inhibition of sphingolipid synthesis by myriocin has been shown to extend yeast 
chronological lifespan because it weakens the PKH1/2-dependent phosphorylation and 





The anti-aging protein kinase Rim15, which is inhibited by the TORC1, PKA and 
PKH1/2 pathways: 
As previously mentioned, the inactivation of Sch9 allows the nuclear translocation of 
Rim15p. Rim15p is and anti-aging protein kinase required for the entry into G0. [14] 
Therefore, activation of Rim15p under conditions of mild intracellular or extracellular 
stress promotes the entry into the state of cellular quiescence and activates expression of 
numerous stress resistance genes, thus extending yeast CLS. [14] RIM15 gene deletion 
impacts key cellular processes in the stationary growth phase. [14] Specifically, lack of 
Rim15p prevents cell cycle arrest in the G1 phase, impairs the entry into G0 and averts 
transcription of stress-inducible genes; all these processes are critical for assuring yeast 
longevity. [14] Deletion of the RIM15 gene also decreases thermotolerance, and 
decelerates the accumulation of trehalose and glycogen. [14]  
Rim15p is inhibited by phosphorylation exerted by the PKA signaling pathway. [14] 
Its nucleocytoplasmic distribution is controlled by the Sch9 branch of the TORC1 
signaling pathway and by the nutrient-sensitive Pho80p-Pho85p signaling pathway. [14]  
The nutrient-sensitive Pho80p-Pho85p signaling pathway phosphorylates Rim15p at 
the threonine 1075 residue in the Bmh2p-binding site of Rim15p; such phosphorylation 
of Rim15p impairs it nuclear import and retains it in the cytoplasm. [14] Sch9 also keeps 
Rim15p in the cytoplasm, by phosphorylating the threonine 1075 residue in its Bmh2p-
binding site; upon the inhibition of TORC1, this site of Rim15p gets dephosphorylated, 
thus enabling Rim15p to enter the nucleus and to activate transcription of many stress-





The pro-aging PKA (protein kinase A) pathway: 
Like the TORC1 pathway, the pro-aging PKA signaling pathway orchestrates key 
longevity-defining processes in chronologically aging yeast and in all other eukaryotes. 
PKA inhibits the anti-aging signaling pathways RIM15 and SNF1; it also inhibits 
autophagy and plays a crucial role in progression through the cell cycle. [12, 14]  
PKA is a heterotetramer compiled of two regulatory (encoded by the BCY1 gene) and 
two catalytic subunits (encoded by three closely related genes, TPK1, TPK2 and TPK3). 
[14] Cyclic AMP (cAMP) must bind to the Bcy1p (inhibitory subunit) in order for the 
Bcy1p to dissociate from the catalytic subunit and therefore allow Tpk1p, Tpk2p and 
Tpk3p (the catalytic subunit) to be activated. [14] Other protein components have been 
found to modulate the PKA signaling pathway in response to certain environmental cues; 
these upstream regulators of the PKA pathway include the transcriptional complex 
Ccr4p-Not, Srb9p and subunits of the Mediator complex of RNA polymerase II. [14] 
The PKA pathway inhibits stress response and some metabolic pathways in yeast 
cells entering the diauxic growth phase. [12] PKA has been found to play a major 
inhibitory role in the transition from the exponential to the diauxic and then to the 
stationary phases of growth. [14] Increased activity of PKA has been shown to shorten 
yeast CLS by attenuating stress response in yeast cells entering the stationary growth 
phase. [14] Decreased activity of PKA activity, on the other hand, is known to extend 







The anti-aging SNF1 (sucrose non-fermenting) pathway: 
SNF1, alike RIM15, is an anti-aging signaling pathway operating in yeast. SNF1 is 
known to regulate transcription of almost 400 genes. [12] Yeast SNF1 is an ortholog of 
the mammalian AMP-activated protein kinase (AMPK); it controls transcription of 
numerous genes by inhibiting transcriptional repressors, directly modulating the core 
transcriptional machinery and stimulating transcriptional activators. [12, 14] SNF1 has 
also been shown to play key roles in other processes, including chromatin modification, 
autophagy, translation and activation of some metabolic pathways. [12] SNF1 complex is 
composed of multiple subunits; they include the regulatory Snf1p and Snf4p subunits, 
Gal83p, Sip1p and Sip2p. [14] Snf1p is autoinhibited when glucose is available to yeast 
cells. [14] When glucose is completely consumed, the regulatory subunit Snf4p 
attenuates such autoinhibition, thus activating Snf1p. [14] Since the SNF1 pathway is 
inhibited when glucose is available to yeast, cells lacking SNF1 activity are unable to 
grow in the presence of carbon sources other than glucose. Therefore, these yeast cells 
die soon after the diauxic shift and exhibit shortened CLS. [14] 
 
The anti-aging ATG (autophagy) pathway: 
The ATG signaling pathway is an anti-aging pathway which is involved in 
autophagy. Autophagy is the process of delivering various cytoplasmic substrates through 
different routes to the lysosome (the vacuole in yeast) for degradation. [17] Several types 
of autophagy are known, such as macroautophagy, microautophagy and chaperone-
mediated autophagy. [17] Once the cytoplasmic substrates (including individual proteins, 




products are released by permeases and recycled within the cytosol. [17] The process of 
autophagy is extremely important when nutrients are scarce. Under such stressful 
conditions, yeast cells enter the G0 phase of cell quiescence. When nutrients become 
readily available, these cells can re-enter the cell cycle once again for cellular division. 
[17] The bioenergetic demands of the cells under stressful conditions of nutrient 
limitation can be fulfilled with the help of autophagy, which allows to renew the energy-
rich compounds so high in demand under such conditions. [17] This implies that 
autophagy is not a destructive process leading to cell death, but rather a cytoprotective 
process of longevity assurance and lifespan maintenance. [17]  
While the pro-aging TORC1 pathway regulates not only autophagy but also many 
other cellular processes, the ATG pathway controls only autophagy. [17] A body of 
evidence indicates that the ATG pathway in chronologically aging yeast undergoes age-
related attenuation. [17] The mechanism underlying such attenuation of this anti-aging 
pathway remains to be established. 
 
1.4 Phytochemicals are secondary metabolites produced by plants and by 
bacteria and fungi that resides within the plants   
Phytochemicals are secondary metabolites with diverse structures. [7] They are 
generated by plants as well as by non-pathogenic endosymbiont microorganisms residing 
within that very plant. [7] The secondary metabolites are of much importance to plants, 
due to the fact that they help the plants to survive. [7] Phytochemicals are of much 




aging and used in my studies were derived from whole plants and, thus, contained a mix 
of phytochemicals. 
Phytochemicals aid plant survival by protecting the plant from environmental 
stresses, herbivorous organisms (by way of attracting predators for such herbivorous 
organisms), microbial infections and environmental pollutants. [7] Phytochemicals are 
also known to attract pollinator organisms and other symbiotes required for plant 
survival. [7] Phytochemicals have been shown to extend longevity in heterotrophic 
organisms across phyla through mechanisms that have been conserved in the course of 
evolution. [7]       
The structurally diverse phytochemicals are divided into eleven different major 
classes which include the following: phenolic compounds, terpenes, betalains, 
polysulfides, organosulfur compounds, indole compounds, select protease inhibitors, 
oxalic and anacardic organic acids, modified purines, quinones, and polyamines. [7]  
Phytochemicals are believed to be an acquired evolutionary adaptation to increase 
the survival of the stationary autotrophic organisms within the many diverse ecological 
niches, and to overcome the many different environmental stresses and/or other survival 
obstacles. [7, 21] Due to the fact that phytochemicals are evolutionarily adaptive to the 
specific stresses within that environment, these secondary metabolites are unique to the 
specific species and/or genera. [7, 21] Thus, phytochemicals do not interfere with the 
primary metabolic requirements for the organism, but rather allow the organism to 
overcome local survival challenges. [21] Moreover, phytochemicals are produced in so-
called “secondary biochemical pathways” which are believed to be evolved to enable 




The necessity of phytochemicals can be highlighted through the energy 
expenditure for their synthesis, where the energy invested is far much in excess compared 
to that required to synthesize primary metabolites. [21] The survival skills benefited to 
the host plant upon the phytochemical synthesis include the following: survival through 
forms of environmental stresses (such as thermal stresses, extreme pH, UV damage, 
osmotic stresses, water deficiency and nutrient deficiency), protection against invading 
species (such as insects, competitor plant species and herbivorous animals), defence 
against infections (including viral, fungal and bacterial ones), protection against 
environmental pollutants, attraction of natural predators for invading species, and 
attraction of symbiotes and pollinators. [7] Furthermore, phytochemicals are produced 
not only by the plant itself, but also by the non-pathogenic endosymbiont microorganisms 
residing within the host plant; this promotes plant survival under conditions in which the 
plant is normally defenceless (that it, in plants exposed to invading species, pathogenic 
infections etc.). [7, 21]       
 
1.5 Phytochemicals extend lifespan in evolutionarily distant organisms by 
targeting an evolutionarily conserved set of longevity-defining cellular processes  
Phytochemicals not only provide added benefits to the survival of plants. A body 
of evidence indicates that these secondary metabolites of plant origin can enhance 
survival and/or extend longevity of various heterotrophic organisms through the targeting 
of an evolutionarily conserved set of longevity-defining cellular processes. [7] As 
mentioned above, phytochemicals are very diverse in nature and may belong to an 




Due to the natural structural diversity of phytochemicals, evolutionarily distant 
heterotrophic organisms use the benefits of phytochemicals to prolong their lifespans. 
Such heterotrophic organisms include S. cerevisiae, fruit flies (Drosophila 
melanogaster), nematodes (Caenorhabditis elegans), fission yeast (Schizosaccharomyces 
pombe), mosquitos, honey bees (Apis mellifera), short-lived fish (Nothobranchius 
furzeri), laboratory mice and rats, multiple lines of cultured human fibroblasts, and 
human peripheral blood mononuclear cells. [7] Many studies support the notion that 
phytochemicals extend longevity in numerous heterotrophic organisms by mechanisms 
which have been conserved throughout the course of evolution. [7] These mechanisms 
target a distinct set of evolutionarily conserved nutrient-sensing signaling pathways.  
Some of these pathways acting in S. cerevisiae have been mentioned above; they 
include the TOR and ATG pathways. These evolutionarily conserved pathways shown to 
be targeted by longevity-extending phytochemicals include the following: the TOR 
pathway, the IIS pathway, the sirtuins-governed protein deacetylation module of the 
longevity signaling network integrating the IIS and TOR pathways, the non-selective 
autophagy pathway for degradation of various cellular organelles and macromolecules, 
and the OSR-1/UNC-43 (CaMKII)/SEK-1 (p38 MAPK) stress-responsive signaling 
pathway. [7]  
Furthermore, phytochemicals can delay aging and extend longevity by postponing 
the onset of a distinct set of cellular processes referred to as “cellular and molecular 
hallmarks of aging”. [7] Specifically, it has been shown that phytochemicals can slow the 




genomic instability, epigenetic alterations, mitochondrial dysfunction, deregulated 
nutrient sensing, altered intercellular communication and cellular senescence. [7]   
Many phytochemicals which have been shown to prolong longevity in 
evolutionarily distant organisms by targeting certain signaling pathways and cellular 
proteins. In brief, such signaling pathways and proteins include the following: sirtuins, 
(Sir1 in S. cerevisiae, SIR-2.1 in the nematode C. elegans, Sir2 in the fruit fly D. 
melanogaster and SIRT1 in mice), TORC1 (in the yeast S. cerevisiae and Sch. pombe), 
Sch9 and Gcn2 (in S. cerevisiae), Sod1 and Sod2 (in S. cerevisiae), and non-selective 
autophagy pathways (in S. cerevisiae, C. elegans and D. melanogaster). [7]      
In the yeast S. cerevisiae, different longevity-extending phytochemicals have been 
shown to cause the following changes to various cellular processes: 1) caffeine enhances 
transcription of genes encoding heat-shock proteins and molecular chaperones; 2) 
cryptotanshinone reduces the intracellular concentrations of ROS; 3) phloridzin causes a 
decline in ROS, increases cell resistance to oxidative stress, and activates transcription of 
the SOD1, SOD2 and SIR2 genes; 4) quercetin decreases ROS as well as lowers cell 
susceptibility to oxidative stress, glutathione oxidation, lipid peroxidation and protein 
carbonylation; 5) resveratrol reduces the frequency of rDNA recombination; and 6) 
spermidine activates transcription of autophagy-related genes, delays the onset of age-
related necrotic cell death, promotes histone H3 deacetylation and decreases activities of 
histone acetyltransferases. [7] Moreover, in another yeast species, Sch. pombe, caffeine 
has been shown to inhibit phosphorylation of ribosomal S6 protein, decelerate protein 
synthesis, alter transcription of numerous nuclear genes, cause cell-cycle arrest in G2 and 




1.6 Phytochemicals can act as interspecies chemical signals that may contribute 
to the evolution of longevity regulation mechanisms within natural ecosystems 
 One hypothesis in regards to phytochemicals and longevity regulation is that 
plants synthesize these secondary metabolites in response to hermetic environmental 
stresses such as dehydration, heat exposure, nutrient deprivation etc. This hypothesis is 
known as the xenohormesis hypothesis. [7] Hormesis is a term used to define a distinct 
type of response of cells and organisms to different doses of stress. In hormetic response, 
low doses of stress promote growth and survival, whereas high doses of the same stress 
impair growth and survival. [7]  
The xenohormesis hypothesis posits that an exposure to low doses of stress allows 
the cell or organism to activate mechanisms that can protect this cell or organism from 
high doses of the same kind of stress. [7] According to this hypothesis, phytochemicals 
released into the environment by plants can create a moderate stress in the heterotrophic 
organisms within the ecosystem. [7] Therefore, phytochemicals can operate as hormetic 
stress agents that enable adaptation and survival of these heterotrophic organisms if they 
are exposed to the higher doses of the same stress. [7] Thus, phytochemicals can act as 
“chemically encoded information” about environmental changes and conditions within a 
particular ecosystem. [7] After being released into this ecosystem by plants, these 
chemical signals can extend longevity of heterotrophic organisms inhabiting the 
ecosystem by modulating some evolutionary conserved of survival. [7] 
The xenohormesis hypothesis suggests that the ability for heterotrophic organisms 
to change their physiology and metabolism in response to mild environmental stresses 




evolutionary selection of mechanisms for maintaining such survival capabilities and, 
thus, for extending longevity of these heterotrophic organisms. [7] In summary, the 
xenohormetic hypothesis states that phytochemicals can function as xenohormetic stress 
signals promoting the survival of heterotrophic organisms within ecosystem and driving 
the evolution of longevity regulation mechanisms. [7]    
 
1.7 The objectives of studies described in this thesis 
Research in the Titorenko laboratory is aimed at using S. cerevisiae as a model 
organism to discover chemical compounds that can slow aging and delay the onset of 
age-related diseases in evolutionarily distant eukaryotic organisms. Some of such 
geroprotective compounds have been previously revealed in natural products extracted 
from certain plants. As a first step towards uncovering novel aging-delaying chemical 
compounds of plant origin, my first objective was to conduct a screen for plant extracts 
that can extend yeast chronological lifespan. My screen revealed six plant extracts that 
increase yeast chronological lifespan considerably more efficiently than any of the 
longevity-extending chemical compounds yet described. Because the rate of aging in 
yeast is controlled by a network of integrated signaling pathways and protein kinases, my 
second objective was to assess how single-gene-deletion mutations eliminating each of 
these pathways and kinases affect the aging-delaying efficiencies of the six plant extracts. 
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2 Discovery of plant extracts that greatly delay yeast chronological aging 
 
2.1 Abstract 
As a first step towards uncovering novel aging-delaying chemical compounds of 
plant origin, I conducted a screen for plant extracts (PEs) that can extend yeast 
chronological lifespan (CLS). My screen revealed six PEs that increase yeast CLS 
considerably more efficiently than any of the longevity-extending chemical compounds 
yet described. These novel lifespan-extending plant extracts include the following: 1) 
0.5% PE4 from Cimicifuga racemosa; 2) 0.5% PE5 from Valeriana officinalis L.; 3) 
1.0% PE6 from Passiflora incarnata L.; 4) 0.3% PE8 from Ginkgo biloba; 5) 0.1% PE12 
from Apium graveolens L.; and 6) 0.1% PE21 from Salix alba. One of these extracts, 
0.1% PE21 from Salix alba, is the most potent longevity-extending pharmacological 
intervention yet described. I demonstrate that, for each of the six lifespan-prolonging 
PEs, the longevity-extending efficacy under caloric restriction (CR) conditions is 
significantly lower than that under non-CR conditions. I conclude that each of these PEs 
could mimic the longevity-extending effect of CR. I provide evidence that each of the six 
PEs is a geroprotector which delays the onset and decreases the rate of yeast 







2.2 Materials and Methods 
 
Yeast strains, media and growth conditions 
The wild-type strain Saccharomyces cerevisiae BY4742 (MAT his31 leu20 lys20 
ura30) from Thermo Scientific/Open Biosystems was grown in a synthetic minimal 
YNB medium (0.67% Yeast Nitrogen Base without amino acids) initially containing 2% 
or 0.5% glucose and supplemented with 20 mg/l histidine, 30 mg/l leucine, 30 mg/l lysine 
and 20 mg/l uracil. Cells were cultured at 30oC with rotational shaking at 200 rpm in 
Erlenmeyer flasks at a “flask volume/medium volume” ratio of 5:1. 
 
CLS assay 
A sample of cells was taken from a culture at a certain day following cell inoculation and 
PE addition into the medium. A fraction of the sample was diluted in order to determine 
the total number of cells using a hemacytometer. Another fraction of the cell sample was 
diluted and serial dilutions of cells were plated in duplicate onto YEP (1% yeast extract, 
2% peptone) plates containing 2% glucose as carbon source. After 2 d of incubation at 
30oC, the number of colony forming units (CFU) per plate was counted. The number of 
CFU was defined as the number of viable cells in a sample. For each culture, the 
percentage of viable cells was calculated as follows: (number of viable cells per ml/total 
number of cells per ml) × 100. The percentage of viable cells in mid-logarithmic growth 




A screen for PEs that can extend yeast CLS 
CLS analysis in the presence of various PEs was performed as described above. A 20% 
stock solution of each PE in ethanol was made on the day of adding this PE to cell 
cultures. For each PE, the stock solution was added to growth medium with 2% glucose 
immediately following cell inoculation into the medium. The final concentration of each 
PE in the medium was 0.02%, 0.04%, 0.06%, 0.08%, 0.1%, 0.3%, 0.5% or 1.0%.  
 
Gompertz mortality function analysis 
The age-specific mortality rate (qx) [22, 24, 25], Gompertz slope or mortality rate 
coefficient (α) [23, 24, 25], and mortality rate doubling time (MRDT) [24, 26] were 
calculated as previously described. The value of qx was calculated as the number of cells 
that lost viability (i.e. are unable to form a colony on the surface of a solid nutrient-rich 
medium) during each time interval divided by the number of viable (i.e. clonogenic) cells 
at the end of the interval. The natural logarithms of the values of qx for each time interval 
were plotted against time. The value of α was calculated as the slope of the Gompertz 
mortality line, whereas the value of MRDT was calculated as ln2/α.        
 
Statistical analysis 
Statistical analysis was performed using Microsoft Excel’s (2010) Analysis ToolPack-
VBA. All data are presented as mean ± SEM. The p values for comparing the means of 
two groups (using an unpaired two-tailed t test) and survival curves (using a two-tailed t 





2.3.1 A screen for PEs that can extend longevity of chronologically aging yeast  
I screened a library of PEs for extracts that can increase yeast CLS. This library includes 
35 different PEs of known origin and properties (Table 2.1 and Table 2.2, respectively). 
To perform the screen for lifespan-extending PEs, I used a robust assay for measuring 
yeast CLS. This assay was similar to the one described previously [27], but the wild-type 
strain BY4742 was cultured in the synthetic minimal YNB medium initially containing 
2% glucose (instead of the nutrient-rich YEP medium supplemented with 0.5% glucose). 
Yeast cells cultured on 2% glucose are not limited in calorie supply; these cells age 
chronologically under so-called non-caloric restriction (non-CR) conditions that 
accelerate aging in different yeast genetic backgrounds, including BY4742 [2, 4, 5].  
          In my screen for longevity-extending PEs, each PE from the library was added to 
growth medium at the time of cell inoculation at a final concentration in the 0.02% to 
1.0% range. Some PEs from the library did not alter the mean and maximum CLS of 
yeast under non-CR conditions at any concentration examined; among these PEs were 
PE9, PE13, PE16, PE22, PE28 and PE36 (Figure 2.2 – Figure 2.5). Many PEs from the 
library shortened the mean and/or maximum CLS of yeast under non-CR conditions at 
final concentrations ranging from 0.08% to 1.0%; among these PEs were PE1 - PE3, PE7, 
PE10, PE11, PE14, PE15, PE17 - PE20, PE24, PE25, PE27, PE29 - PE35 and PE37 
(Figure 2.1 – Figure 2.5). 6 of the 35 PEs from the library significantly increased both 
the mean and maximum CLS of yeast under non-CR conditions if added at final 
concentrations ranging from 0.04% to 1.0% (Figure 2.1 – Figure 2.3). A group of these 
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longevity-extending PEs included the following extracts: 1) 0.5% PE4 from Cimicifuga 
racemosa (Figure 2.1, Figure 2.6A, Figure 2.8A, Figure 2.8B); 2) 0.5% PE5 from 
Valeriana officinalis L. (Figure 2.1, Figure 2.6B, Figure 2.8A, Figure 2.8B); 3) 1.0% 
PE6 from Passiflora incarnata L. (Figure 2.1, Figure 2.6C, Figure 2.8A, Figure 2.8B); 
4) 0.3% PE8 from Ginkgo biloba (Figure 2.1, Figure 2.6D, Figure 2.8A, Figure 2.8B); 
5) 0.1% PE12 from Apium graveolens L. (Figure 2.2, Figure 2.6E, Figure 2.8A, Figure 
2.8B); and 6) 0.1% PE21 from Salix alba (Figure 2.3, Figure 2.6F, Figure 2.8A, Figure 
2.8B). None of the six lifespan-prolonging PEs affected growth rates in logarithmic (L) 
and post-diauxic (PD) phases or impacted the maximum cell density in stationary (ST) 
phase of yeast cultures under non-CR conditions on 2% glucose (Figure 2.9). Thus, the 
observed lifespan extension by each of these PEs is unlikely to be caused by its ability to 
decrease growth rate or to make yeast more resistant to toxic substances accumulated 
during culturing in the synthetic minimal YNB medium. 
 
Table 2.1. A list of plant extracts that have been used in this study. 
Abbreviated name  Botanical name Plant part used Commercial source 
PE1 Echinacea purpurea Whole plant Idunn Technologies 
PE2 Astragalus membranaceous Root Idunn Technologies 
PE3 Rhodiola rosea L. Root Idunn Technologies 
PE4 Cimicifuga racemosa Root and rhizome Idunn Technologies 
PE5 Valeriana officinalis L. Root Idunn Technologies 
PE6 Passiflora incarnate L. Whole plant Idunn Technologies 
PE7 Polygonum cuspidatum Root and rhizome Idunn Technologies 
PE8 Ginkgo biloba Leaf Idunn Technologies 
PE9 Zingiber officinale Roscoe Rhizome Idunn Technologies 
PE10 Theobroma cacao L. Cacao nibs Idunn Technologies 
PE11 Camellia sinensis L. Kuntze Leaf Idunn Technologies 
PE12 Apium graveolens L. Seed Idunn Technologies 
PE13 Scutellaria baicalensis Root Idunn Technologies 
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PE14 Euterpe oleracea Fruit Idunn Technologies 
PE15 Withania somnifera Root and leaf Idunn Technologies 
PE16 Phyllanthus emblica Fruit Idunn Technologies 
PE17 Camellia sinensis Leaf Idunn Technologies 
PE18 Pueraria lobata Root Idunn Technologies 
PE19 Silybum marianum Seed Idunn Technologies 
PE20 Eleutherococcus senticosus Root and stem Idunn Technologies 
PE21 Salix alba Bark Idunn Technologies 
PE22 Glycine max L. Bean Idunn Technologies 
PE24 Calendula officinalis Flower Idunn Technologies 
PE25 Salvia miltiorrhiza Root Idunn Technologies 
PE27 Panax quinquefolium Root Idunn Technologies 
PE28 Harpagophytum procumbens Root Idunn Technologies 
PE29 Olea europaea L. Leaf Idunn Technologies 
PE30 Gentiana lutea Root Idunn Technologies 
PE31 Piper nigrum Fruit Idunn Technologies 
PE32 Aesculus hippocastanum  Seed Idunn Technologies 
PE33 Mallus pumila Mill. Fruit Idunn Technologies 
PE34 Fragaria spp. Fruit Idunn Technologies 
PE35 Ribes nigrum Leaf Idunn Technologies 
PE36 Dioscorea opposita Root Idunn Technologies 
















PE1 Extraction solvent: ethanol (75%)/water (25%). Extract ratio: 4/1. Composition: 
natural extract, maltodextrin. 
PE2 Extraction solvent: denatured ethanol (70%)/water (30%). Extract ratio: 10/1. 
Composition: natural extract (40-50%), gum arabic (50-60%).  
PE3 Extraction solvent: ethanol (60-80%)/water (40-20%). Extract ratio: 15-20/1. 
Composition: natural extract (80-100%), maltodextrin (0-20%). 
PE4 Extract ratio: 6-8/1. Composition: natural extract (28-38%), maltodextrin (60-
70%), tricalcium phosphate (0-5%). 
PE5 Extraction solvent: denatured ethanol/water. Extract ratio: ~ 6/1. Composition: 
natural extract, maltodextrin, silica (0-1%). 
PE6 Extraction solvent: water (100%). Extract ratio: 4/1. Composition: natural 
extract, maltodextrin. 
PE7 Extraction solvent: ethanol (80%)/water (20%). Extract ratio: 40/1. 
Composition: natural extract (90-100%), maltodextrin (0-10%). 
PE8 Extraction solvent: ethanol/water. Extract ratio: 50/1. Composition: natural 
extract.  
PE9 Extraction solvent: ethanol/water. Composition: natural extract (96%), 
gingerols (4%). 
PE10 Natural powder/final product ratio: 2-3/1. Composition: natural powder. 
PE11 Extraction solvent: ethyl acetate (90%)/water (10%). Extract ratio: 6/1. 
Composition: natural extract (100%). 
PE12 Extraction solvent: ethanol (90%)/water (10%). Extract ratio: 8/1. Composition: 
natural extract, maltodextrin, modified starch, silica. 
PE13 Extraction solvent: ethanol/water. Extract ratio: 4/1. Composition: natural 
extract. 
PE14 Extraction solvent: ethanol/water. Extract ratio: 4/1. Composition: natural 
extract. 
PE15 Extraction solvent: water. Extract ratio: 9/1. Composition: withanolide 
glycoside conjugates (10%), oligosaccharides (32%), free withanolides (0.5%). 
PE16 Extraction solvent: water. Composition: hydrolysable tannins (>60%), including 
Emblicanin-A, Emblicanin-B, Punigluconin, Pedunculagin.  
PE17 Composition: tea polyphenols (>90%), including epigallocatechin gallate 
(>40%). 
PE18 Composition: flavonoids (>40%), including puerarin. 
PE19 Extraction solvent: ethanol/water. Composition: silymarin (>80%). 
PE20 Extraction solvent: water. Composition: eleutheroside B+E (>0.8%). 
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PE21 Extraction solvent: ethanol/water. Composition: salicin (>25%). 
PE22 Composition: isoflavones (40%). 
PE24 Composition: lutein (>5%). 
PE25 Composition: tanshinones, isotanshinones, cryptotanshinone, 
isocryptotanshinone, dihydrotanshinone, hydroxytanshinones.  
PE27 Composition: ginsenosides (10%, by HPLC-UV), quintozene-free. 
PE28 Extraction solvent: ethanol/water. Extract ratio: 40/1. Composition: 
harpagosides (20%, by HPLC-UV). 
PE29 Extraction solvent: ethanol (70%)/water (30%). Extract ratio: 5-10/1. 
Composition: natural extract, maltodextrin, silica (0.2%). 
PE30 Composition: isogentisin (0.04%). 
PE31 Extraction solvent: ethanol. Extract ratio: 10/1. Composition: piperine (>90%). 
PE32 Composition: aescin (20%). 
PE33 Extraction solvent: ethanol (70%)/water (30%). Extract ratio: 120-130/1. 
Composition: natural extract (60-70%), maltodextrin (30-40%). 
PE34 Extract ratio: 5/1. Composition: natural extract, including polyphenols (>2%). 
PE35 Extraction solvent: water. Composition: polyphenols (15%, by HPLC-UV). 
PE36 Composition: diosgenine (>16%, by HPLC-UV). 































































































































































2.3.2 For each of the six lifespan-prolonging PEs, the longevity-extending efficacy 
under CR conditions is significantly lower than that under non-CR conditions  
Chronologically aging yeast grown under CR conditions on 0.5% glucose are known to 
live longer than yeast cultured under non-CR conditions on 2% glucose. Such ability of 
the CR diet to extend CLS has been reported for yeast cultured in media of various 
nutrient compositions [2, 4, 5]. I found that, if the CR diet is administered by culturing 
yeast in the YNB medium initially containing 0.5% glucose, it significantly increases 
both the mean and maximum CLS of S. cerevisiae (Figure 2.7A – Figure 2.7C). I 
discovered that 0.5% PE5 and 0.1% PE21 (but not 0.5% PE4, 1.0% PE6, 0.3% PE8 or 
0.1% PE12) extend the mean CLS of yeast grown under CR conditions (Figure 2.7D – 
Figure 2.7I, Figure 2.8C). I also revealed that 0.5% PE5, 1.0% PE6 and 0.1% PE21 (but 
not 0.5% PE4, 0.3% PE8 or 0.1% PE12) extend the maximum CLS of yeast grown under 
CR conditions (Figure 2.7D – Figure 2.7I, Figure 2.8D). Akin to their effects under 
non-CR conditions, none of the six lifespan-prolonging PEs influenced growth rates in L 
and PD phases or altered the maximum cell density in ST phase of yeast cultures under 
CR conditions on 0.5% glucose (Figure 2.10). Importantly, each of the six lifespan-
prolonging PEs extended both the mean and maximum CLS of yeast cultures under non-
CR conditions on 2% glucose to a significantly higher extent than those of yeast under 
CR at 0.5% glucose (Figure 2.8A – Figure 2.8F). This observation indicates that each of 
these PEs could mimic the longevity-extending effect of CR.       
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2.3.3 Each of the six longevity-extending PEs is a geroprotector which delays the 
onset and slows the progression of yeast chronological aging by eliciting a hormetic 
stress response 
As I found, PE4, PE5, PE6, PE8, PE12 and PE21 greatly extend the mean CLS of yeast 
cultured under non-CR conditions (Figure 2.6A, Figure 2.8A, Figure 2.8B, Figure 2.1 – 
Figure 2.3). Mean lifespan is believed to be directly proportional to the survival rates of 
organisms in the population during development and maturity stages of organismal aging; 
mean lifespan is likely to be under control of certain extrinsic (environmental) factors 
[22, 28 - 30]. Thus, it is conceivable that PE4, PE5, PE6, PE8, PE12 and PE21 decrease 
the extrinsic rate of yeast chronological aging prior to cell entry into quiescence or 
senescence. 
          Furthermore, I revealed that PE4, PE5, PE6, PE8, PE12 and PE21 also 
substantially increase the maximum CLS of yeast grown under non-CR conditions 
(Figure 2.1 – Figure 2.3, Figure 2.6A, Figure 2.8A). Maximum lifespan is believed to 
reflect the duration of “healthy” life period (i.e. healthspan) during 
quiescence/senescence stage of organismal aging; maximum lifespan is likely to be 
controlled by certain intrinsic (cellular and organismal) longevity modifiers [1, 22, 28, 
29, 31, 32]. One could therefore conclude that PE4, PE5, PE6, PE8, PE12 and PE21 also 
decrease the intrinsic rate of yeast chronological aging after cell entry into quiescence or 
senescence.     
          My analysis of the Gompertz mortality function further validated the above 
conclusion that PE4, PE5, PE6, PE8, PE12 and PE21 significantly reduce the rate of 
yeast chronological aging. Indeed, I found that each of these longevity-extending PEs 
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causes a substantial decrease in slope of the Gompertz mortality rate (also known as 
mortality rate coefficient α) and a considerable increase in the mortality rate doubling 
time (MRDT) (Figure 2.11A – Figure 2.11G). Such changes in the values of α and 
MRDT are characteristic of interventions that decrease the rate of progression through the 
process of biological aging [22, 23 - 26].  
          Noteworthy, my analyses of how different concentrations of PE4, PE5, PE6, PE8, 
PE12 and PE21 impact yeast longevity under non-CR conditions revealed that each of 
them causes a so-called “hormetic” stress response in chronologically aging yeast with 
respect to longevity. Indeed, the dose-response curves (i.e. the curves that reflect 
relationships between PE concentrations and mean or maximum CLS) for PE4, PE5, 
PE8, PE12 and PE21 were inverted U-shaped, whereas the dose-response curve for PE6 
was J-shaped (Figure 2.1 – Figure 2.3). Such nonlinear and biphasic dose-response 
curves denote a hormetic kind of stress response, in which 1) lower (hormetic) 
concentrations of a chemical compound increase the survival of a cell or an organism by 
stimulating biological processes that allow to maintain cellular or organismal stress at a 
level which is below a threshold of toxicity; while 2) higher concentrations of this 
chemical compound decrease the survival of a cell or an organism by creating stress 
which exceeds such threshold [7, 45 - 48]. 
 
2.4 Discussion 
In studies described in this chapter of my Thesis, I performed a screen for PEs capable of 
extending longevity of the chronologically aging yeast S. cerevisiae. My screen revealed 

















increase yeast CLS. I demonstrated that each of these PEs is a geroprotector which delays 
the onset and slows the progression of yeast chronological aging by eliciting a hormetic 
stress response. My findings imply that the efficiency of longevity extension by PE4, 
PE5, PE6, PE8, PE12 or PE21 greatly exceeds that for any of the 42 chemical compounds 
known to increase lifespan in yeast, filamentous fungi, nematodes, fruit flies, daphnias, 
mosquitoes, honey bees, fish, mammals and cultured human cells (Table 2.3). Indeed, 
under non-CR conditions these longevity-extending PEs increase the mean and maximum 
CLS of yeast by 145% - 475% and 80% - 369%, respectively (Figure 2.8A, Figure 2.8B, 
Table 2.3); the corresponding rows in Table 2.3 are highlighted in yellow. In contrast, 
any of the 42 currently known lifespan-extending chemical compounds has been shown 
to extend cellular and/or organismal lifespan in evolutionarily distant eukaryotes much 
less efficiently, within the 5% to 75% range (Table 2.3) [45 – 105]. Only two chemical 
compounds, spermidine under non-CR conditions and lithocholic acid under CR-
conditions, have been reported to exhibit the lifespan-extending efficiencies that are 
comparable to those for PE4, PE5, PE6, PE8 and PE12 (Table 2.3) [72, 73, 102]. 
Specifically, both these pharmacological interventions were demonstrated to increase the 
RLS and/or CLS of yeast and human peripheral blood mononuclear cells by 83% - 200%; 
the corresponding rows in Table 2.3 are highlighted in green. Of note, PE21 appears to 
be the most potent longevity-extending pharmacological intervention presently known. It 
increases the mean and maximum CLS of yeast by 475% and 369%, respectively (Figure 
2.8A, Figure 2.8B, Table 2.3). 
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In the future, it would be important to further explore the following key aspects of 
the mechanisms through which each of the six longevity-extending PEs slows biological 
aging. 
First, it is intriguing to identify the individual chemical compounds responsible 
for the ability of each of these PEs to delay the onset and decrease the rate of yeast 
chronological aging. Such identification is already underway in the Titorenko laboratory; 
of note, it is conceivable that only some combinations of certain chemicals composing 
these PEs (but not individual chemical compounds per se) can be responsible for their 
extremely high efficiencies as aging-delaying interventions. 
Second, it is important to investigate how various combinations of the six 
longevity-extending PEs with each other and with presently known aging-delaying 
chemical compounds alter the extent of CLS extension in yeast. These studies may 
identify such combinations of various pharmacological interventions that impose 
substantial additive or synergistic effects on the efficiencies with which organismal 
lifespan and healthspan can be prolonged. 
Third, the ongoing studies in the Titorenko laboratory and in the laboratories of 
his collaborators indicate that the six longevity-extending PEs also extend longevities of 
other eukaryotic model organisms, delay the onset of age-related diseases and/or exhibit 
anti-tumor effects. In this regard, it needs to be mentioned that genetic, dietary and 
pharmacological interventions known to delay aging in yeast and other eukaryotes have 
been shown to selectively kill cultured human cancer cells and/or decrease the incidence 
of cancer [106 - 119]. The challenge for the future is to define mechanisms through 
which the six geroprotective PEs prolong healthy lifespan and decelerate tumorigenesis. 
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Table 2.3. Percent increase of lifespan by geroprotective PEs discovered in this 
study and by longevity-extending chemical compounds that have been previously 
identified. 
 
PE or chemical 
compound 
% increase of lifespan* [reference] Organism exhibiting 
lifespan increase 
0.5% PE4 195% (mean CLS) [this study] 
100% (max** CLS) [this study] 
S. cerevisiae  
 
0.5% PE5 185% (mean CLS) [this study] 
87% (max CLS) [this study] 
S. cerevisiae 
 
1.0 % PE6 180% (mean CLS) [this study] 
80% (max CLS) [this study] 
S. cerevisiae 
 
0.3% PE8 145% (mean CLS) [this study] 
104% (max) [this study] 
S. cerevisiae 
 
0.1% PE12 160% (mean CLS) [this study] 
107% (max CLS) [this study] 
S. cerevisiae 
 
0.1% PE21 475% (mean CLS) [this study] 
369% (max CLS) [this study] 
S. cerevisiae 
 
Acteoside  24 - 25% (female); 16 - 18% (male) (mean OLS) [45] 
9 - 13% (female); 9 - 15% (male) (max OLS) [45] 
The fruit fly Drosophila 
melanogaster 
Butein  55% (mean RLS) [46] S. cerevisiae 
Caffeic acid 11% (mean OLS) [47] The nematode 
Caenorhabditis elegans 
Caffeine 8% (median CLS) [48] S. cerevisiae  
46% (mean CLS) [49] 




52% (mean OLS) [50]; 37% (mean OLS) [51] 
29% (median OLS) [50] 
C. elegans 
Catechin  15% (mean OLS) [52] 
14% (median OLS) [52] 
C. elegans 





13% - 39% (mean OLS) [54] C. elegans 
26% (females; mean OLS); 16% (males; mean OLS) [55, 56] 
75% (median OLS) [57] 
D. melanogaster, 
including 5 different 
models of the 
Alzheimer’s disease  
Crocin 37% - 58% (max OLS) [58]  
 
Dalton’s lymphoma 
ascites bearing mice 
Cryptotanshinone 34% (mean CLS) [59] S. cerevisiae 
Cyanidin 2% - 6% (max RLS; untreated cells); 14 - 21% (max RLS; WI-38 human diploid 
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prematurely aging cells pre-treated with H2O2) [60] fibroblasts  
Diallyl trisulfide 13% (mean OLS) [61] C. elegans 
Ellagic acid 9% (mean OLS); 11% - 13% (median OLS) [62] C. elegans 
Epigallocatechin 
gallate 
10% - 14% (mean OLS) [63]   C. elegans 
Epicatechin 42% (mean OLS) [64] 
3% (max OLS) [64]  
D. melanogaster 
8% (mean OLS) [64] Obese diabetic mice 
Ferulsinaic acid 18% (mean CLS) [65] 
42% (max OLS) [65] 
C. elegans 
Fisetin 31% (mean RLS) [46] S. cerevisiae 
6% (mean OLS) [66] 
6% (median OLS) [66] 
C. elegans 
Fucoxanthin 14% (mean OLS) [67] 
24% (max OLS) [67] 
C. elegans 
33% - 49% (females; median OLS); 33% (males; median 
OLS) [67] 
22% - 27% (females; max OLS); 12% - 17% (males; max 
OLS) [67] 
D. melanogaster 
Gallic acid 12% (mean OLS) [62] 
14% (median OLS) [62] 
C. elegans 
HDTIC-1, HDTIC-2 14% - 38% (max RLS)  [68] Human fetal lung 
diploid fibroblasts  
Icariin, icariside II 31% (mean OLS) [69] C. elegans 
Kaempferol  10% (mean OLS) [66] 
6% (median OLS) [66] 
C. elegans 
Lipoic acid 21% (median OLS) [70] C. elegans 
12% (females; average OLS); 15% (females; median OLS) 
[71] 
4% (males; average OLS); 4% (males; median OLS) [71] 
D. melanogaster 
Lithocholic acid 146% (mean CLS) [72, 73] 
100% (max CLS) [72, 73] 
S. cerevisiae 
Metformin 40% (median OLS) [74] C. elegans 
38% (mean OLS) [75] 




78% (mean CLS) [76] 
63% (max CLS) [76] 
S. cerevisiae 
Mianserin  25% (mean OLS) [77] C. elegans 
Myricetin  15% (mean OLS) [78] 
17% (median OLS) [78] 




10% (median OLS) [79] 
32% (max OLS) [79] 
Mouse model of the 
Alzheimer’s disease 
12% (median OLS) [80] Male mice 
12% (mean OLS) [81] D. melanogaster 
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42% - 64% (mean OLS) [82] Mosquitoes  
Oleuropein  15% (max RLS) [83] Human embryonic 
fibroblasts 
Phloridzin  35% (mean RLS) [84] 
41% (max RLS) [84] 
S. cerevisiae 
Propyl gallate  41% (median OLS) [70] C. elegans 
Quercetin  60% (mean CLS) [85] S. cerevisiae 
15% (mean OLS) [86] 
18% (mean OLS) [87] 
14% (median OLS) [88] 
C. elegans 
5% (max RLS) [89]   Human embryonic 
fibroblasts 
Rapamycin  16% (mean RLS) [90] 
36% (mean CLS) [91] 
S. cerevisiae 
17% (mean OLS) [92] 
23% (max OLS) [92] 
D. melanogaster 
13% (females; mean OLS); 9% (males; mean OLS) [93] 
14% (females; max OLS); 9% (males; max OLS) [93] 
Mice 
Reserpine 64% (mean OLS); 50% (max OLS) [94] C. elegans 
52% (mean OLS) [95] C. elegans model of the 
Alzheimer’s disease 
Resveratrol 61% (mean RLS) [46] S. cerevisiae 
10% (mean OLS) [96] C. elegans 
20% (females; mean OLS); 16% (males; mean OLS) [96] D. melanogaster 
56% (median OLS) [97] 
59% (max OLS) [97] 
The short-lived fish 
Nothobranchius furzeri 
38% (mean OLS) [98] The honey bee Apis 
mellifera 
4% (max OLS) [99] Mice on a high-calorie 
diet  
Rosmarinic acid 10% (mean OLS) [47] C. elegans 
SkQ1 38% (mean CLS) [100] 
16% (max CLS) [101] 
The fungus Podospora 
anserina  
69% (mean CLS) [101] 
64% (max CLS) [100] 
The crustacean 
Ceriodaphnia affinis 
13% (females; mean OLS) [100] 
7% (females; max OLS) [100] 
D. melanogaster 
43% (mean OLS) [100] 
58% (max OLS) [100] 
p53-Deficient mice 
52% (mean OLS) [100] 
34% (max OLS) [100] 
Tumor-bearing 
immunodeficient mice 
Sodium nitroprusside 60% (max RLS) [101] Human peripheral 
blood mononuclear 
cells  
Spermidine 200% (mean CLS) [102] S. cerevisiae 
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183% (mean RLS) [102] 
17% (max RLS) [102] 
15% (mean OLS) [102] 
14% (max) OLS) [102]  
C. elegans 
30% (mean OLS) [102] 
8% (max OLS) [102] 
D. melanogaster 
178% (max RLS) [102] Human peripheral 
blood mononuclear 
cells  
Tannic acid 18% - 25% (mean OLS) [50, 62, 103]; 18% (median OLS) 
[62, 103] 
59% (max OLS) [50] 
C. elegans 
Taxifolin 26% (median OLS) [70] C. elegans 
Trolox 15% (median OLS) [70] C. elegans 
Tyrosol 21% (mean OLS); 21% (median OLS) [104] 
11% (maximum OLS) [104] 
C. elegans 
Valproic acid 35% (mean OLS) [105] 
42% (max OLS) [105] 
C. elegans 
 
* Chronological or replicative lifespan (CLS or RLS, respectively) of cell cultures or 
organismal lifespan (OLS). 
 










Studies described in chapter 2 of my Thesis have revealed six plant extracts that 
slow yeast chronological aging more efficiently than any chemical compound yet 
described. The rate of aging in yeast is controlled by an evolutionarily conserved network 
of integrated signaling pathways and protein kinases. In studies described in this chapter 
of my Thesis, I assessed how single-gene-deletion mutations eliminating each of these 
pathways and kinases affect the aging-delaying efficiencies of the six plant extracts. My 
findings imply that these extracts slow aging in the following ways: 1) plant extract 4 
(PE4) decreases the efficiency with which the pro-aging TORC1 pathway inhibits the 
anti-aging SNF1 pathway; 2) plant extract 5 (PE5) mitigates two different branches of the 
pro-aging PKA pathway; 3) plant extract 6 (PE6) coordinates processes that are not 
assimilated into the network of presently known signaling pathways/protein kinases; 4) 
plant extract 8 (PE8) diminishes the inhibitory action of PKA on SNF1; 5) plant extract 
12 (PE12) intensifies the anti-aging protein kinase Rim15; and 6) plant extract 21 (PE21) 
inhibits a form of the pro-aging protein kinase Sch9 that is activated by the pro-aging 






3.2 Materials and Methods 
 
Yeast strains, media and growth conditions 
The wild-type strain Saccharomyces cerevisiae BY4742 (MAT his31 leu20 lys20 
ura30) and single-gene-deletion mutant strains in the BY4742 genetic background (all 
from Thermo Scientific/Open Biosystems) were grown in a synthetic minimal YNB 
medium (0.67% (w/v) Yeast Nitrogen Base without amino acids) initially containing 2% 
(w/v) glucose and supplemented with 20 mg/l histidine, 30 mg/l leucine, 30 mg/l lysine 
and 20 mg/l uracil. Cells were cultured at 30oC with rotational shaking at 200 rpm in 
Erlenmeyer flasks at a “flask volume/medium volume” ratio of 5:1. 
 
Aging-delaying PEs 
0.5% (w/v) PE4 from Cimicifuga racemosa, 0.5% (w/v) PE5 from Valeriana officinalis 
L., 1.0% (w/v) PE6 from Passiflora incarnata L., 0.3% (w/v) PE8 from Ginkgo biloba, 
0.1% (w/v) PE12 from Apium graveolens L. and 0.1% (w/v) PE21 from Salix alba were 
used. A 20% (w/v) stock solution of each PE in ethanol was made on the day of adding 
this PE to cell cultures. For each PE, the stock solution was added to growth medium 
with 2% (w/v) glucose immediately following cell inoculation into the medium. 
 
CLS assay 
A sample of cells was taken from a culture at a certain day following cell inoculation and 
PE addition into the medium. A fraction of the sample was diluted in order to determine 
the total number of cells using a hemacytometer. Another fraction of the cell sample was 
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diluted and serial dilutions of cells were plated in duplicate onto YEP (1% yeast extract, 
2% peptone) plates containing 2% glucose as carbon source. After 2 d of incubation at 
30oC, the number of colony forming units (CFU) per plate was counted. The number of 
CFU was defined as the number of viable cells in a sample. For each culture, the 
percentage of viable cells was calculated as follows: (number of viable cells per ml/total 
number of cells per ml) × 100. The percentage of viable cells in mid-logarithmic growth 
phase was set at 100%. 
 
Gompertz mortality function analysis 
The age-specific mortality rate (qx) [22, 24, 25], Gompertz slope or mortality rate 
coefficient (α) [23, 24, 25], and mortality rate doubling time (MRDT) [24, 26] were 
calculated as previously described. The value of qx was calculated as the number of cells 
that lost viability (i.e. are unable to form a colony on the surface of a solid nutrient-rich 
medium) during each time interval divided by the number of viable (i.e. clonogenic) cells 
at the end of the interval. The natural logarithms of the values of qx for each time interval 
were plotted against time. The value of α was calculated as the slope of the Gompertz 
mortality line, whereas the value of MRDT was calculated as ln2/α.        
 
Statistical analysis 
Statistical analysis was performed using Microsoft Excel’s (2010) Analysis ToolPack-
VBA. All data are presented as mean ± SEM. The p values for comparing the means of 
two groups (using an unpaired two-tailed t test) and survival curves (using a two-tailed t 





3.3.1 The rationale of my experimental approach 
PE4, PE5, PE6, PE8, PE12 and PE21 may have different effects on signaling 
pathways and/or protein kinases integrated into the longevity-defining network. To 
identify the pathways and kinases through which each of these PEs slows yeast 
chronological aging, I assessed such effects. Specifically, I elucidated how mutations 
eliminating these signaling pathways and protein kinases affect the efficiency with which 
each of the six PEs extends yeast CLS. Table 3.1 shows the single-gene-deletion 
mutations used in this study. This table also demonstrates how each of the mutations 
impacts different longevity-defining signaling pathways and protein kinases, and how it 
alters yeast CLS. I investigated the effects of the following single-gene-deletion 
mutations shown in Table 3.1: 1) tor1Δ, which impairs the pro-aging TORC1 pathway 
and increases CLS [120, 121]; 2) ras2Δ, which weakens the pro-aging PKA pathway and 
extends CLS [123]; 3) rim15Δ, which eliminates the anti-aging protein kinase Rim15 and 
shortens CLS [122]; 4) sch9Δ, which removes the pro-aging protein kinase Sch9 and 
increases CLS [122]; 5) pkh2Δ, which weakens the pro-aging PKH1/2 pathway and 
extends CLS [124, 125]; 6) snf1Δ, which impairs the anti-aging SNF1 pathway and 
decreases CLS [126, 129]; and 7) atg1Δ, which deteriorates the anti-aging ATG pathway 
and shortens CLS [127, 128]. 
A logical framework for identifying signaling pathways and/or protein kinases 
controlled by each of the six longevity-extending PEs is schematically depicted in Figure 
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3.1. Pro-aging signaling pathways or protein kinases A and B in this figure are displayed 
in black color, whereas their anti-aging counterparts C and D are shown in grey color. 
One could envision that if PE(x) extends yeast CLS by inhibiting a pro-aging 
pathway/protein kinase A, this PE: 1) is unable to extend longevity of the ΔA mutant 
strain lacking this signaling pathway/protein kinase (Figure 3.1B); 2) exhibits an additive 
or synergistic longevity-extending effect with the ΔB mutation, which eliminates the pro-
aging signaling pathway/protein kinase B (Figure 3.1B); and 3) is able to prolong 
longevity of the ΔC or ΔD mutant strain, which lacks the anti-aging signaling 
pathway/protein kinase C or D (respectively), but to a lesser extent than that of wild-type 
(WT) strain (Figure 3.1B). It is also plausible that that if PE(y) extends yeast CLS by 
activating an anti-aging pathway/protein kinase C, this PE: 1) displays an additive or 
synergistic longevity-extending effect with the ΔA or ΔB mutation, which eliminates the 
pro-aging signaling pathway/protein kinase A or B (respectively) (Figure 3.1C); 2) is 
incapable of increasing longevity of the ΔC mutant strain deficient in the anti-aging 
signaling pathway/protein kinase C (Figure 3.1C); and 3) can extend longevity of the ΔD 
mutant strain, which lacks the anti-aging signaling pathway/protein kinase D, although 






Table 3.1. Single-gene-deletion mutations used in this study and their known effects 









Effect on longevity 
tor1Δ Tor1 TORC1 Extended [120, 
121] 
ras2Δ Ras2 PKA Extended [123] 
rim15Δ Rim15 TORC1, PKA, PKH1/2 Shortened [122] 
sch9Δ Sch9 TORC1, PKA Extended [122] 
pkh2Δ Pkh2 PKH1/2 Extended [124, 
125] 
snf1Δ Snf1 SNF1 Shortened [126, 
129] 




























PE4 are replicated in all graphs of Figure 3.2A and Figure 3.3). PE4 caused a decrease 
in slope of the Gompertz mortality rate (also known as mortality rate coefficient α) and 
an increase in the mortality rate doubling time (MRDT) for ras2Δ, sch9Δ and pkh2Δ 
(Figure 3.4; note that data for the mock-treated WT strain and for the WT strain cultured 
with PE4 are replicated in all graphs of this figure). Such changes in the values of α and 
MRDT are characteristic of interventions that decrease the rate of biological aging [23-
26, 28, 29]. Thus, PE4 delays yeast chronological aging independently of the pro-aging 
PKA pathway, the pro-aging PKH1/2 pathway or the pro-aging protein kinase Sch9. 
PE4 extended longevities of the rim15Δ and atg1Δ mutant strains, although to a 
lesser extent than that of WT strain (Figure 3.2A, Table 3.2, Table 3.3, Figure 3.3). PE4 
reduced the value of α and elevated the value of MRDT for rim15Δ and atg1Δ, though 
not as significantly as for WT (Figure 3.4). Hence, PE4 slows yeast chronological aging 
not through the anti-aging protein kinase Rim15 or the anti-aging ATG pathway. 
PE4 was unable to extend the CLS of tor1Δ and snf1Δ (Figure 3.2A, Table 3.2, 
Table 3.3, Figure 3.3) and did not alter the values of α or MRDT for these mutant strains 
(Figure 3.4). I concluded that PE4 delays yeast chronological aging via the pro-aging 
TORC1 pathway and the anti-aging SNF1 pathway, by weakening the known [130, 131] 































































Table 3.2. p Values for pairs of survival curves of a yeast strain cultured with or 
without the indicated plant extract (PE). Survival curves shown in Figure 3.2A – 
Figure 3.17A were compared. The survival curve of a strain cultured with the indicated 
PE was considered statistically different from the survival curve of the same strain 
cultured without it if the p value was less than 0.05; such p values are displayed in red 
color. For each pair of survival curves with the p value less than 0.05, the survival rate of 
the strain cultured with the indicated PE was higher than the survival rate of the same 
strain cultured without it. The p values for comparing pairs of survival curves were 





Same strain with the indicated PE 
PE4 PE5 PE6 PE8 PE12 PE21 
WT < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
tor1Δ 0.8899 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
ras2Δ < 0.0001 0.3664 < 0.0001 0.41888 < 0.0001 < 0.0001 
rim15Δ 0.0042 0.0168 < 0.0001 0.0184 0.6453 < 0.0001 
sch9Δ < 0.0001 < 0.0001 < 0.0001 0.0006 < 0.0001 0.0306 
pkh2Δ < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
snf1Δ 0.5873 0.0075 < 0.0001 0.7124 0.0132 < 0.0001 
atg1Δ 0.0027 0.0061 < 0.0001 0.0086 0.0208 < 0.0001 
 
Table 3.3. p Values for pairs of survival curves of the wild-type (WT) and mutant 
strain, both cultured in the presence of the indicated PE. Survival curves shown in 
Figure 3.2A – Figure 3.17A were compared. The survival curve for the WT strain 
cultured with the indicated PE was considered statistically different from the survival 
curve for the mutant strain cultured with this PE if the p value was less than 0.05. The p 
values less than 0.05 are displayed in red color if the survival rate of the mutant strain 
cultured with the indicated PE was higher than the survival rate of the WT strain cultured 
with this PE. The p values less than 0.05 are displayed in blue color if the survival rate of 
the mutant strain cultured with the indicated PE was lower than the survival rate of the 
WT strain cultured with this PE. The p values for comparing pairs of survival curves 
were calculated as described in Materials and methods.     
 
















0.0827 0.0002 < 0.0001 0.0004 0.0007 < 0.0001 < 0.0001 
 
















< 0.0001 0.0724 < 0.0001 0.0008 < 0.0001 < 0.0001 0.0004 
 
PE6 tor1Δ + ras2Δ + rim15Δ sch9Δ + pkh2Δ + snf1Δ + atg1Δ + 
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PE6 PE6 + PE6 PE6 PE6 PE6 PE6 
WT + 
PE6 
< 0.0001 < 0.0001 0.0364 0.0008 < 0.0001 < 0.0001 < 0.0001 
 
















< 0.0001 0.0124 < 0.0001 0.0032 < 0.0001 < 0.0001 0.0008 
 
















0.0003 0.0011 < 0.0001 0.0018 < 0.0001 0.0004 0.0012 
 
















0.0036 0.0062 0.0109 < 0.0001 0.0044 0.0009 0.0086 
 
3.3.3 PE5 slows chronological aging by impeding two branches of the PKA 
pathway 
PE5 displayed an additive longevity-extending effect with the sch9Δ mutation, 
and increased yeast CLS in synergy with the tor1Δ and pkh2Δ mutations (Figure 3.5A, 
Table 3.2, Table 3.3, Figure 3.6; note that data for the mock-treated WT strain and for 
the WT strain cultured with PE5 are replicated in all graphs of Figure 3.5A and Figure 
3.6). PE5 decreased the values of α and increased the values of MRDT for 
chronologically aging cultures of strains carrying each of these three mutations (Figure 
3.7; note that data for the mock-treated WT strain and for the WT strain cultured with 
PE5 are replicated in all graphs of this figure). Therefore, PE5 slows aging not through 
TORC1, PKH1/2 or Sch9. 
PE5 increased CLS of the rim15Δ, snf1Δ and atg1Δ mutant strains, however to a 
lesser extent than that of WT strain (Figure 3.5A, Table 3.2, Table 3.3, Figure 3.6). PE5 
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decreased the value of α and increased the value of MRDT strains carrying each of these 
mutations, although not as considerably as for WT (Figure 3.7). Thus, PE5 slows aging 





























PE5 was unable to extend the CLS of ras2Δ (Figure 3.5A, Table 3.2, Table 3.3, 
Figure 3.6) and did not alter the values of α or MRDT for this mutant strains (Figure 
3.7). Hence, PE5 delays aging by weakening two branches of the PKA signaling pathway 
(Figure 3.5B). One of these branches involves the Rim15-independent processes of 
autophagy inhibition and protein translation activation in the cytosol, whereas the other 
branch attenuates the Rim15-diven establishment of an anti-aging transcriptional program 




















































3.3.4 PE6 delays chronological aging by coordinating processes that are not 
integrated into the network of longevity-defining signaling pathways/protein kinases 
PE6 exhibited additive longevity-extending effects with the rim15Δ, sch9Δ and 
atg1Δ mutations, and extended longevity synergistically with the tor1Δ, ras2Δ, pkh2Δ 
and snf1Δ mutations (Figure 3.8A, Table 3.2, Table 3.3, Figure 3.9; note that data for 
the mock-treated WT strain and for the WT strain cultured with PE6 are replicated in all 
graphs of Figure 3.8A and Figure 3.9). PE6 lowered the values of α and raised the 
values of MRDT for chronologically aging cultures of strains carrying each of these 
seven mutations (Figure 3.10; note that data for the mock-treated WT strain and for the 
WT strain cultured with PE6 are replicated in all graphs of this figure). Thus, PE6 delays 
aging by activating anti-aging processes and/or inhibiting pro-aging processes that are not 
assimilated into the network of presently known signaling pathways/protein kinases 
(Figure 3.8B). 
Although rim15Δ, snf1Δ and atg1Δ exhibited decreased CLS in the absence of 
PE6, this PE extended the CLS of each of these mutant strains to a greater extent than 
that of WT strain (Figure 3.8A, Table 3.2, Table 3.3, Figure 3.9, Figure 3.10). It is 
possible that the efficiency with which PE6 activates anti-aging processes and/or inhibits 
pro-aging processes outside of the network in the absence of Rim15, Snf1 or Atg1 may 





























































3.3.5 PE8 slows chronological aging by weakening the inhibitory effect of PKA on 
SNF1 
PE8 displayed an additive longevity-extending effect with the sch9Δ mutation, 
and increased yeast CLS in synergy with the tor1Δ and pkh2Δ mutations (Figure 3.11A, 
Table 3.2, Table 3.3, Figure 3.12; note that data for the mock-treated WT strain and for 
the WT strain cultured with PE8 are replicated in all graphs of Figure 3.11A and Figure 
3.12). PE8 decreased the values of α and increased the values of MRDT for 
chronologically aging cultures of strains carrying each of these three mutations (Figure 
3.13; note that data for the mock-treated WT strain and for the WT strain cultured with 
PE8 are replicated in all graphs of this figure). Therefore, PE8 slows aging independently 
of Sch9, TORC1 and PKH1/2. 
PE8 increased CLS of the rim15Δ and atg1Δ mutant strains, though not as 
considerably as for WT (Figure 3.11A, Table 3.2, Table 3.3, Figure 3.12). PE8 lowered 
the values of α and raised the values of MRDT for chronologically aging cultures of 
strains carrying each of these mutations (Figure 3.13). Hence, PE8 delays aging not 
through Rim15 or ATG. 
PE8 was unable to extend the CLS of ras2Δ and snf1Δ (Figure 3.11A, Table 3.2, 
Table 3.3, Figure 3.12) and did not alter the values of α or MRDT for these mutant 
strains (Figure 3.13). Thus, PE8 slows aging via PKA and SNF1, by attenuating the 





3.3.6 PE12 delays chronological aging by stimulating Rim15 
PE12 increased yeast CLS synergistically with the pkh2Δ mutation, and displayed 
additive longevity-extending effects with the tor1Δ, ras2Δ and sch9Δ mutations (Figure 
3.14A, Table 3.2, Table 3.3, Figure 3.15; note that data for the mock-treated WT strain 





























































and Figure 3.15). PE12 reduced the values of α and augmented the values of MRDT for 
chronologically aging cultures of strains carrying each of these four mutations (Figure 
3.16; note that data for the mock-treated WT strain and for the WT strain cultured with 
PE12 are replicated in all graphs of this figure). Hence, PE12 slows aging not through 
PKH1/2, TORC1, PKA or Sch9. 
PE12 extended longevities of the snf1Δ and atg1Δ mutant strains, although to a 
lesser extent than that of WT strain (Figure 3.14A, Table 3.2, Table 3.3, Figure 3.15). 
PE12 decreased the value of α and increased the value of MRDT strains carrying each of 
these mutations, however not as considerably as for WT (Figure 3.16). Therefore, PE12 
delays aging independently of SNF1 and ATG. 
PE12 was unable to extend the CLS of rim15Δ (Figure 3.14A, Table 3.2, Table 
3.3, Figure 3.15) and did not alter the values of α or MRDT for this mutant strain 

































































3.3.7 PE21 slows chronological aging by inhibiting a PKH1/2-sensitive form of 
Sch9 
PE21 increased yeast CLS in synergy with the pkh2Δ mutation, and displayed 
additive longevity-extending effects with the tor1Δ and ras2Δ mutations (Figure 3.17A, 
Table 3.2, Table 3.3, Figure 3.18; note that data for the mock-treated WT strain and for 
the WT strain cultured with PE21 are replicated in all graphs of Figure 3.17A and Figure 
3.18). PE21 decreased the values of α and increased the values of MRDT for 
chronologically aging cultures of strains carrying each of these three mutations (Figure 
3.19; note that data for the mock-treated WT strain and for the WT strain cultured with 
PE21 are replicated in all graphs of this figure). Thus, PE21 slows aging independently of 
PKH1/2, TORC1 and PKA. 
PE21 increased CLS of the rim15Δ, snf1Δ and atg1Δ mutant strains, although to a 
slightly lesser extent than that of WT (Figure 3.17A, Table 3.2, Table 3.3, Figure 3.18). 
PE12 lowered the values of α and raised the values of MRDT for chronologically aging 
cultures of strains carrying each of these mutations, however somewhat less considerably 
than those for WT (Figure 3.19). Hence, PE12 delays aging not through Rim15, SNF1 or 
ATG. 
PE21 extended the CLS (Figure 3.17A, Table 3.2, Table 3.3, Figure 3.18), 
decreased the value of α (Figure 3.19) and increased the value of MRDT (Figure 3.19) 
significantly less efficiently for sch9Δ than it did for WT. I therefore concluded that PE21 








































































A hypothetical model for how the six PEs delay yeast chronological aging via the 
longevity-defining network of signaling pathways/protein kinases emerges from my 
analysis. This model is depicted schematically in Figure 3.20. The model suggests that 
these PEs delay aging as follows: 1) PE4 attenuates the inhibitory effect of TORC1 on 
SNF1; 2) PE5 weakens both the Rim15-dependent and Rim15-independent branches of 
the PKA signaling pathway; 3) PE6 activates anti-aging processes and/or inhibits pro-
aging processes that are not integrated into the network of signaling pathways/protein 
kinases; 4) PE8 attenuates the inhibitory effect of PKA on SNF1; 5) PE12 activates 
Rim15; and 6) PE21 inhibits a PKH1/2-sensitive form of Sch9. Thus, geroprotective 
chemical compounds from some plants can slow yeast chronological aging by targeting 
different hubs, nodes and/or links of the longevity-defining network that integrates 
certain evolutionarily conserved signaling pathways and protein kinases. In the future, it 
would be important to validate the above hypothesis by investigating how each of the six 
aging-delaying PEs impacts the physical links that connect individual hubs and nodes of 
the chronological aging network shown in Figure 3.20. These links are known to be 
mainly activating or inhibiting phosphorylations and dephosphorylations of certain target 
proteins that are transiently or permanently reside in various cellular locations, including 
the plasma membrane, vacuole, nucleus, mitochondria or cytosol [120 – 141].    
I found that each of the six PEs delays aging through different signaling pathways 
and/or protein kinases (Figure 3.20). It is possible therefore that if these PEs are mixed in 





















sulfoxide, lithocholic acid and cryptotanshinone [132, 141 – 154]. One could envision 
therefore that certain combinations of these chemical compounds and the six PEs may 
have additive or synergistic effects on the aging-delaying proficiencies of each other. The 
ongoing studies in the Titorenko laboratory address the validity of this assumption. 
          The evolutionarily conserved nutrient-sensing signaling pathways that accelerate 
chronological aging in yeast (Figure 3.20) are known to stimulate chronological 
senescence and geroconversion of post-mitotic human cells; these pathways are likely to 
expedite organismal aging and cancer development in humans [155 - 161]. Moreover, 
genetic and pharmacological manipulations that attenuate these signaling pathways and 
delay chronological aging in yeast are known to decelerate chronological senescence and 
geroconversion of post-mitotic human cells; it is believed that these manipulations may 
also delay organismal aging and tumorigenesis in humans [155 - 161]. Thus, some of the 
six geroprotective PEs that slow down yeast chronological aging through these signaling 
pathways (Figure 3.20) may prolong healthy lifespan and decelerate tumorigenesis. 
The challenge for the future is to assess whether any of the six PEs can delay the 
onset and progression of chronic diseases associated with human aging. Among such 
diseases are arthritis, diabetes, heart disease, kidney disease, liver dysfunction, 
sarcopenia, stroke, neurodegenerative diseases (including Parkinson's, Alzheimer's and 
Huntington's diseases), and many forms of cancer [141, 143, 144, 146, 162 – 179]. 
Because the major aspects of aging and age-related pathology are conserved across phyla 
[142 - 146, 163 – 165], it is noteworthy that this study, recent findings [154] and some 
ongoing research in the Titorenko laboratory have revealed several features of the six PEs 
as potential interventions for decelerating chronic diseases of old age. These features are 
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the following: 1) the six PEs are caloric restriction (CR) mimetics that imitate the aging-
delaying effects of the CR diet in yeast under non-CR conditions; 2) they are 
geroprotectors that slow yeast aging by eliciting a hormetic stress response; 3) they 
extend yeast longevity more efficiently than any lifespan-prolonging chemical compound 
yet described; 4) they delay aging through signaling pathways and protein kinases 
implicated in such age-related pathologies as type 2 diabetes, neurodegenerative diseases, 
cardiac hypertrophy, cardiovascular disease, sarcopenia and cancers; and 5) they extend 
longevity and delay the onset of age-related diseases in other eukaryotic model 
organisms. The potential of using the six aging-delaying PEs for delaying the onset of 
age-related diseases in humans is further underscored by the fact that the Health Canada 
government agency classifies these PEs as safe for human consumption and recommends 
to use five of them as health-improving supplements with clinically proven benefits to 
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